Trevena CEO to present at the 14th Annual Needham Healthcare Conference

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company, today announced Maxine Gowen, Ph.D., its chief executive officer, will present a company overview at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 10:00 a.m. EDT in New York.

To access the live audio webcast of the presentation, please visit the “Investors” section of the Company's website at Following the conclusion of the presentation, the webcast will be archived for 30 days.

About Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena is developing four biased ligand product candidates it has identified - TRV027 to treat acute heart failure (Phase 2b), TRV130 to treat moderate to severe acute pain intravenously (Phase 2b), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for treatment-refractory migraine and other CNS disorders (preclinical).

Investor Contacts:
Trevena, Inc.
Jonathan Violin
Director of investor relations
(610) 354-8840 x231
Argot Partners
Andrea Rabney
President and chief executive officer
(212) 600-1902
Media Contact:
Argot Partners
Eliza Schleifstein
(917) 763-8106

Source: Trevena, Inc.